Coya Therapeutics, Inc. Common Stock (NASDAQ:COYA) — Market Cap & Net Worth
Market Cap & Net Worth: Coya Therapeutics, Inc. Common Stock (COYA)
Coya Therapeutics, Inc. Common Stock (NASDAQ:COYA) has a market capitalization of $108.84 Million ($108.84 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18961 globally and #4319 in its home market, demonstrating a 12.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Coya Therapeutics, Inc. Common Stock's stock price $5.03 by its total outstanding shares 23457183 (23.46 Million). Review COYA total liabilities to assess the company's total debt and financial obligations.
Coya Therapeutics, Inc. Common Stock Market Cap History: 2022 to 2026
Coya Therapeutics, Inc. Common Stock's market capitalization history from 2022 to 2026. Data shows growth from $111.14 Million to $117.99 Million (2.80% CAGR).
Index Memberships
Coya Therapeutics, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #537 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #1840 of 3165 |
Weight: Coya Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Coya Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Coya Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.12x
Coya Therapeutics, Inc. Common Stock's market cap is 17.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $173.82 Million | $6.00 Million | -$7.99 Million | 28.96x | N/A |
| 2024 | $134.41 Million | $3.55 Million | -$14.88 Million | 37.82x | N/A |
| 2025 | $136.05 Million | $7.95 Million | -$21.23 Million | 17.12x | N/A |
Competitor Companies of COYA by Market Capitalization
Companies near Coya Therapeutics, Inc. Common Stock in the global market cap rankings as of June 19, 2026.
Key companies related to Coya Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Coya Therapeutics, Inc. Common Stock Historical Marketcap From 2022 to 2026
Between 2022 and today, Coya Therapeutics, Inc. Common Stock's market cap moved from $111.14 Million to $ 117.99 Million, with a yearly change of 2.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $117.99 Million | -13.28% |
| 2025 | $136.05 Million | +1.22% |
| 2024 | $134.41 Million | -22.67% |
| 2023 | $173.82 Million | +56.40% |
| 2022 | $111.14 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Coya Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $108.84 Million USD |
| MoneyControl | $108.84 Million USD |
| MarketWatch | $108.84 Million USD |
| marketcap.company | $108.84 Million USD |
| Reuters | $108.84 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneou… Read more